Company Presentation - J.P. Morgan Healthcare ... - MorphoSys
Company Presentation - J.P. Morgan Healthcare ... - MorphoSys
Company Presentation - J.P. Morgan Healthcare ... - MorphoSys
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
MOR208<br />
Clinical Development<br />
Clinical Trial Design<br />
�� Multi-centre Multi-centre, open-label open-label, multi-dose multi-dose, single-arm phase 1, 1 dose-escalation<br />
study in USA<br />
� Patients with chronic lymphocytic leukemia, who have not responded to or<br />
hhave bbecome refractory f t tto previous i th therapies i<br />
� Objectives:<br />
� Primary objectives: Investigate maximum tolerated dose dose, safety and<br />
tolerability, pharmacokinetics and immunogenicity<br />
� Secondary objectives: Assess preliminary anti-tumor activity<br />
� Xencor funds phase 1 trial from $13 m up-front payment<br />
� Final data expected in 2012<br />
Corporate<br />
Technology Pipeline AbD Serotec<br />
© <strong>MorphoSys</strong> AG Page 12
Change language